Therapies – clinical testing
C109 – C125
- C109: Case Report: treatment of insulinoma related hypoglycaemia with Everolimus (RAD001) therapy
- C110: Efficient trial design for new cancer therapies
- C111: Breathlessness training in patients with intrathoracic malignancy: a comparison of low and high intensity programmes
- C112: Clinical outcomes in poor performance patients with advanced ovarian and primary peritoneal cancers.
- C113: A comparison of three sources of information to guide the Bayesian design of a trial in the rare cancer Merkel-cell carcinoma
- C114: A phase II study of NY-ESO-1 ISCOMATRIX® vaccine and NY-ESO-1 ISCOMATRIX® vaccine followed by recombinant fowlpox NY-ESO-1 (rF-NY-ESO-1) in patients with high-risk, resected melanoma
- C115: Should all patients receiving capecitabine be screened for hypertrigylceridaemia? A prospective audit of incidence and severity
- C116: A trial of continuous low dose chemotherapy combined with celecoxib for patients with advanced cancer
- C117: Evidence that hexa histidine tags on therapeutic proteins are not immunogenic in patients
- C118: Challenges of identifying cancer patients for randomised controlled trials (RCTs) from urology clinics: what lessons can we learn from SPARE? (CRUK/07/011)
- C119: A retrospective study demonstrating improvement in 5-year and post-relapse survival in ovarian cancer patients over a 24-year period
- C120: A Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide) intravenously (IV) every 3 weeks
- C121: Maintenance therapy following chemotherapy of relapsed ovarian cancer: a randomised placebo-controlled phase II trial with the angiogenesis inhibitor BIBF 1120
- C122: Final results of a phase I study of the Heat Shock Protein 90 inhibitor Alvespimycin (17-DMAG) in patients with advanced, solid tumours
- C123: Preliminary activity in adrenocortical tumour (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumours
- C124: Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study
- C125: A first-in-man, dose-escalating Phase I study of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor in patients with advanced solid tumours
